Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Efficacy of Lecanemab in Patients With Parkinson's Disease With Coexistent Alzheimer's Disease
Authors not listed
Yonsei University · 2026
Abstract
This study aimed to determine the efficacy of amyloid clearance of lecanemab in patients with Parkinson's disease (PD) with amyloid co-pathology. Lecanemab, an anti-amyloid monoclonal antibody, was apporoved by the US FDA in July 2023 and in South Korea in May 2024, as a disease-modifying therapy based on its clinical efficacy and reduction of amyloid plaques in patients with early-stage Alzheimer's disease (AD). AD pathology is also common in PD, and approximately 35% of patients with PD dementia have co-existing AD pathology. Currently, no mediations have been developed to slow the progression of PD. Therefore, this study aimed to determine whether reducing the amyloid burden in patients with PD with co-exsistent AD pathology could potentially slow disease progression. To test it, patients with PD with mild cognitive impairment or early dementia, who were confirmed to have amyloid deposition through amyloid imaging, would be enrolled as a treatment arm, and the degree of reduction of amyloid plaque after 18 months of lecanemab administration would be investigated.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2026). Efficacy of Lecanemab in Patients With Parkinson's Disease With Coexistent Alzheimer's Disease. <em>Yonsei University</em>. https://clinicaltrials.gov/study/NCT07544953
Vancouver
Anonymous. Efficacy of Lecanemab in Patients With Parkinson's Disease With Coexistent Alzheimer's Disease. Yonsei University. 2026.
BibTeX
@misc{anon2026Effica,
title = {Efficacy of Lecanemab in Patients With Parkinson's Disease With Coexistent Alzheimer's Disease},
author = {Anonymous},
journal = {Yonsei University},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Memory Pharmaceuticals 2007
Open access · US-GOV
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Pharmacodynamics/Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Fixed Dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in Patients With Mild to Moderate Alzheimer's Disease
European Journal of Medicinal Chemistry 2021
Citation only
Alzheimer’s disease and its treatment by different approaches: A review
Shanghai 10th People's Hospital 2024
Open access · US-GOV
Clinical Safety and Efficacy of FMT in the Treatment of Alzheimer's Disease
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2001
Open access · US-GOV
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
JHSPH Center for Clinical Trials 2009
Open access · US-GOV
A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease
Memory Pharmaceuticals 2005
Open access · US-GOV